LogicBio Therapeutics, Inc. (LOGC)
| Market Cap | 188.31M |
| Revenue (ttm) | 3.45M |
| Net Income (ttm) | -32.62M |
| Shares Out | 25.36M |
| EPS (ttm) | -1.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $5.88 |
| Previous Close | $6.22 |
| Change ($) | -0.34 |
| Change (%) | -5.47% |
| Day's Open | 6.20 |
| Day's Range | 5.64 - 6.36 |
| Day's Volume | 167,228 |
| 52-Week Range | 5.00 - 10.00 |
LEXINGTON, Mass., March 30, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare ...
LEXINGTON, Mass., March 15, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage genetic medicine company pioneering gene delivery and gene editing...
LEXINGTON, Mass., Feb. 26, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare a...
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment ...
Gene-editing concern LogicBio Therapeutics, Inc. has lost ~$90 million of market cap since an IND clinical hold was placed on its LB-001 candidate in February 2020. The hold was lifted in August 2020 wi...
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery today anno...
- IND for LB-001 in methylmalonic acidemia (MMA) cleared in August 2020 , with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021 - Fast Track designation for LB-001 in MMA r...
Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill unmet needs for patients Fast Track designation facilitates development of new therapies that tr...
LEXINGTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery...
LEXINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery...
LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery...
LEXINGTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted deliver...
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pat...
LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pat...
– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform –
FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Pat...
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
NEW YORK, May 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and ...
CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pat...
LogicBio: A Speculative Buy For Their GeneRide Platform Based Gene Therapies
CAMBRIDGE, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pati...
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients – – Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 – – Established research collaboration wi...
CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pati...
About LOGC
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene thera... [Read more...]
| Industry Biotechnology | IPO Date Oct 19, 2018 |
| CEO Frederic Chereau | Employees 39 |
| Stock Exchange NASDAQ | Ticker Symbol LOGC |
Analyst Forecasts
According to 4 analysts, the average rating for LOGC stock is "Strong Buy." The 12-month stock price forecast is 20.25, which is an increase of 244.39% from the latest price.